Risk-based monitoring (RBM) has become a cornerstone of innovative trial execution. Supported by the FDA and EMA, this approach can deliver greater efficiency while upholding data quality and patient safety. Our solution, Data-driven Trial Execution, leverages enhanced data review processes and timely insights from our breakthrough technology, Quintiles Infosario® Clinical, to provide holistic, near-real-time views of your patient, study, site and program-level data. This helps you cut trial timelines and reduce costs by up to 25 percent compared with traditional monitoring approaches.
Fact Sheet February 12, 2015